‘We Can’t Wait Years’: European Medtechs Urge EU Co-Legislators To Move At Pace On MDR/IVDR
Petra Zoellner, regulatory affairs director at MedTech Europe, provides an update on the pace and direction of travel of recent European Commission proposals and actions for the EU medtech sector, while emphasizing the need for speed.
Medtech Insight - March 4, 2026

PK Takes Control Of UK-Based Supplements Player HealthAid
Avista and Damier-backed PK snaps up UK-based HealthAid with the deal also including its US operation.
HBW Insight - March 4, 2026

Neuroscience Drug Development Funding Poised For A Comeback
At BIO’s Investor and Growth Summit, investors acknowledged the tough funding environment for early stage neuroscience, but said there are signs of increasing interest in the space.
Scrip - March 4, 2026

Hikma Gets Backing Of US Solicitor General As Supreme Court Considers Skinny-Label Dispute
As the US Supreme Court prepares to review litigation over skinny-label generics with carved-out indications, Hikma has once again won the backing of the US solicitor general for its position.
Generics Bulletin - March 4, 2026

Bayer Backs Newer Launches To Drive Growth Despite Challenging 2025
Newer launches in its pharmaceuticals division such as Nubeqa and Kerendia will be core to Bayer’s 2026 growth strategy.
Scrip - March 4, 2026

Cipla And Kemwell Shake Hands On Further ‘Biologics’ Development In India
Cipla will form a 60:40 joint venture with Kemwell Biopharma to develop, manufacture and commercialize biologics for global markets. The India-based venture will leverage Kemwell’s Bengaluru biologics facility and support development, licensing, and export of biologic products.
Generics Bulletin - March 4, 2026

First US Flovent Generic Offers Glenmark CGT Bonus
Glenmark says it plans to launch imminently the first US generic fluticasone propionate rival to Flovent, for which it has just received FDA approval – with an added bonus of 180 days of Competitive Generic Therapy exclusivity.
Generics Bulletin - March 4, 2026

Moderna And Genevant/Arbutus Settle LNP Patent Dispute For $950m+
The payout could increase to $2.25bn if Moderna loses an ongoing appeal that would shift $1.3bn in liability to US taxpayers, making it the largest patent settlement in pharma history.
Scrip - March 4, 2026

Why ‘Platform Or Perish’ Is Cell Therapy’s New Reality
Something fundamental has shifted in cell therapy investment over the past 18 months. No longer about which science works, it has evolved around the question of which business model pharma believes it can scale. Increasingly, that question is being answered before a single patient is enrolled.
In Vivo - March 4, 2026

Geneva Forum: Self-Care Pays, But Who’s Financing It?
Self-care is gaining momentum worldwide, as the Global Self-Care Federation Forum in Geneva made clear. But a central question remains: if self-care is to deliver on its promise of healthier populations and more sustainable healthcare systems, who will finance it?
HBW Insight - March 4, 2026

Parexel Execs On Trials In War Zones, Biotech ‘Green Shoots’, China Action And DCT Rework
Parexel’s CEO Peyton Howell and India chief Sanjay Vyas talked to Scrip about trials amid global upheavals, the slowdown in big pharma decision-making and pivot in some cases to the FSP model, an evolving DCT definition and India opportunities.
Scrip - March 4, 2026

Aqemia Bets Physics, Not Data, Is The Key To Novel Drug Discovery
Aqemia uses proprietary physics-based solvers paired with generative AI to discover genuinely novel drug candidates, bypassing historical training data to crack targets others cannot.
In Vivo - March 4, 2026

UCB In $1bn-Plus Deal For Antengene’s Anti-CD19/CD3 T-Cell Engager
UCB is paying $1bn-plus for global rights to Antengene's ATG-201, an anti-CD19/CD3 T-cell engager, as it looks to build its strength in immunology.
Scrip - March 4, 2026

Kyowa Kirin Discontinues Rocatinlimab Trials Due To Malignancy Risk
Kyowa Kirin halts all trials with its OX40-targeting antibody rocatinlimab following Kaposi’s sarcoma cases and Amgen's recent return of the asset.
Scrip - March 4, 2026

Sanofi Replenishes cGVHD Pipeline With Sino Biopharm’s JACK/ROCK Inhibitor
Deal Snapshot: By paying Sino Biopharm up to $1.5bn, Sanofi appears to planning for its new Chinese partner’s JACK/ROCK inhibitor rovadicitinib to pick up where its own Rezurock left off in first-line, chronic graft-versus-host disease.
Scrip - March 4, 2026

US FDA Sets Stage For Input On Supplement Industry’s ‘New Technologies And Approaches’
Industry groups acknowledge a March 27 public meeting has potential to influence how firms can expand product lines with additional ingredients and formulations allowed under DSHEA. FDA acknowledges industry’s interest in introducing additional ingredients.
HBW Insight - March 4, 2026

Beiersdorf ‘Rebalancing’ Nivea As Global Skin Market Weakness, China Reset, Dampen Brand Sales
German company Beiersdorf AG has launched an initiative to strategically 'rebalance' its Nivea skin care brand to return it to an ‘elevated growth trajectory.’
HBW Insight - March 4, 2026